Soltani, SaberZakeri, Amir MohammadKarimi, Mohammad RezaRezayat, Sara AkhavanAnbaji, Fateme ZomorodiTabibzadeh, AlirezaYousefi, ParastooZakeri, ArminJafarpour, AliNorouzi, MehdiErfani, YousefPoortahmasebi, Vahdat2020-11-182020-11-182020-05Soltani Saber, Zakeri Amir Mohammad, Karimi Mohammad Reza, Rezayat Sara Akhavan, Anbaji Fateme Zomorodi, Tabibzadeh Alireza, Yousefi Parastoo, Zakeri Armin, Jafarpour Ali, Norouzi Mehdi, Erfani Yousef, Poortahmasebi Vahdat. A Systematic Literature Review of Current Therapeutic Approaches for COVID-19 Patients. Journal of Pharmaceutical Research International. 2020 May; 32(7): 13-252456-91192231-2919http://imsear.searo.who.int/handle/123456789/215987Background:In December 2019, the pneumonia outbreak reported in Wuhan, Hubei Province, China. WHO introduced a novel coronavirus and the virus named Severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) in January 2020. There are not any specific antiviral agents for coronavirus disease 19 (COVID‐19). Objective:Our review aimed to discuss treatment options and the efficacy of currently prescribed drugs and supportive care in COVID‐19 patients. Study Design:A literature review of the articles in the Web of Science, PubMed, Scopus and EMBASE conducted. Results: Lopinavir/ritonavir combination was the most frequently used drug, followed by Arbidol and Oseltamivir and Methylprednisolone. Lopinavir/Ritonavir outcome showed the fever and respiratory infection improve in day two and day eight, respectively. Also, negative PCR of SARS‐CoV‐2 in days six and 7day was seen and finally these patients discharged in 10 days. Conclusions: Lopinavir/Ritonavir was the most improving administrated antiviral combination, which might be a good option for COVID-19 due to its availability. Although supportive care such as O2supplementary and IV fluid therapy has improved outcomes. There are not evidence forsuggesting a new treatment or a new drug, which mean the necessity of further investigations for drug research in a clinical trial for a conclusion about the optimum treatmentCoronavirusSARS virussevere acute respiratory syndrome-related coronavirus 2COVID-19antiviral agentsdrug therapytherapeutics.Journal ArticleIndiaDepartment of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, IranResearch Center for Clinical Virology, Tehran University of Medical Sciences, Tehran, Iran.Students’ Scientific Research Center, Tehran University of Medical Sciences, Tehran, IranPediatric Surgery Research Center, Research Institute for Children’s Health, Shahid Beheshti University of Medical Sciences, Tehran, IranDepartment of Health Care Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, IranDepartmentof Cell and Molecular Biology, School of Biology College of Science, University of Tehran, Tehran, IranDepartment of Virology, Iran University of Medical Sciences, Tehran, IranDepartment of Hematology, Faculty of Medical Sciences, Tarbiat Modares University,Tehran, IranDepartment of Medical Laboratory Sciences, School of Allied Medical Sciences, Tehran University Medical Sciences, Tehran, IranInfectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, IranLiver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, IranDepartment of Bacteriology and Virology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.